The EMSY threonine 207 phospho-site is required for EMSY-driven suppression of DNA damage repair
Open Access
- 13 January 2017
- journal article
- Published by Impact Journals, LLC in Oncotarget
- Vol. 8 (8) , 13792-13804
Abstract
// <![CDATA[ $('.header-date').hide();$('#titleAuthors').hide();$('#abstractHeader').hide(); // ]]> Petar Jelinic1, Laura A. Eccles2, Jill Tseng3, Paulina Cybulska3, Monicka Wielgos1, Simon N. Powell2, Douglas A. Levine1 1Laura and Isaac Perlmutter Cancer Center, Division of Gynecologic Oncology, Department of OB/GYN, NYU Langone Medical Center, New York, USA 2Departments of Radiation Oncology and Molecular Biology, Memorial Sloan Kettering Cancer Center, New York, USA 3Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, USA Correspondence to: Douglas A. Levine, email: douglas.levine@nyumc.org Keywords: EMSY, BRCAness, PKA, BRCA2, DNA repair Received: September 02, 2016 Accepted: January 04, 2017 Published: January 13, 2017 ABSTRACT BRCA1 and BRCA2 are essential for the repair of double-strand DNA breaks, and alterations in these genes are a hallmark of breast and ovarian carcinomas. Other functionally related genes may also play important roles in carcinogenesis. Amplification of EMSY, a putative BRCAness gene, has been suggested to impair DNA damage repair by suppressing BRCA2 function. We employed direct repeat GFP (DR-GFP) and RAD51 foci formation assays to show that EMSY overexpression impairs the repair of damaged DNA, suggesting that EMSY belongs to the family of BRCAness proteins. We also identified a novel phospho-site at threonine 207 (T207) and demonstrated its role in EMSY-driven suppression of DNA damage repair. In vitro kinase assays established that protein kinase A (PKA) directly phosphorylates the T207 phospho-site. Immunoprecipitation experiments suggest that EMSY-driven suppression of DNA damage repair is a BRCA2-independent process. The data also suggest that EMSY amplification is a BRCAness feature, and may help to expand the population of patients who could benefit from targeted therapies that are also effective in BRCA1/2-mutant cancers.Keywords
This publication has 39 references indexed in Scilit:
- The Breast Cancer Oncogene EMSY Represses Transcription of Antimetastatic microRNA miR-31Molecular Cell, 2014
- The protein kinase Akt1 regulates the interferon response through phosphorylation of the transcriptional repressor EMSYProceedings of the National Academy of Sciences, 2012
- The DNA damage response and cancer therapyNature, 2012
- EMSY overexpression disrupts the BRCA2/RAD51 pathway in the DNA-damage response: implications for chromosomal instability/recombination syndromes as checkpoint diseasesMolecular Genetics and Genomics, 2011
- Purified human BRCA2 stimulates RAD51-mediated recombinationNature, 2010
- Negative Regulation of AKT Activation by BRCA1Cancer Research, 2008
- AKT1 Inhibits Homologous Recombination by Inducing Cytoplasmic Retention of BRCA1 and RAD51Cancer Research, 2008
- Amplification of EMSY, a novel oncogene on 11q13, in high grade ovarian surface epithelial carcinomasGynecologic Oncology, 2006
- Hallmarks of 'BRCAness' in sporadic cancersNature Reviews Cancer, 2004
- Detailed map of a region commonly amplified at 11q13→q14 in human breast carcinomaCytogenetic and Genome Research, 1997